adjournment - English-Tagalog new dictionary
https://english_tagalog_new.enacademic.com/1121/adjournment
via Academic summary
https://english_tagalog_new.enacademic.com/1121/adjournment
Look at other dictionaries: adjournment — I noun adjournal, break, continuation, deferment, dilatio, discontinuation, extension, hold over, intermission, ...via Academic summary
academic2.ru 🎓²
Photo
academic2.ru full
Telegram: Contact @enacademic
Saving page now...
https://t.me/enacademic/592904
As it appears live July 10, 2020 4:16:06 PM UTC https://web.archive.org/static/images/logo_WM.png
Telegram: Contact @enacademic
Saving page now...
https://t.me/enacademic/592904
As it appears live July 10, 2020 4:16:06 PM UTC https://web.archive.org/static/images/logo_WM.png
Translation — gelten — from german — to russian
https://ift.tt/2AO90os
via Academic summary
https://ift.tt/2AO90os
Translation — gelten — from german — to russian — 1Mediavia Academic summary
Academic Dictionaries and Encyclopedias
Translation — gelten — from german — to russian
Translation — gelten — from german — to russian — 1
بنت حلوة | Academic Dictionaries and Encyclopedias
https://arabic_english.enacademic.com/17097/%D8%A8%D9%86%D8%AA+%D8%AD%D9%84%D9%88%D8%A9
via Academic summary
https://arabic_english.enacademic.com/17097/%D8%A8%D9%86%D8%AA+%D8%AD%D9%84%D9%88%D8%A9
Remember this site. All languages Abkhaz Adyghe Afrikaans Ainu Akan Albanian Alsatian Altaic Arabic Aragonese Armenian Aromanian Asturian Aymara Azerbaijani Bagobo Bashkir Basque Belarusian...via Academic summary
Academic Dictionaries and Encyclopedias
بنت حلوة
n. cookie
aircraft surge launch and recovery ⚗ from english
https://ift.tt/2zH1ScY
via Academic summary
https://ift.tt/2zH1ScY
Look at other dictionaries: aircraft surge launch and recovery — Specific procedures used at USAF bases to provide increased launch and recovery rates in instrument flight rules (IFR) conditions. ASLAR is based on reduced separation between aircraft, which is based on time or distance.Mediavia Academic summary
Academic Dictionaries and Encyclopedias
Translation — aircraft surge launch and recovery — from english —
Translation — aircraft surge launch and recovery — from english — — 1
academic2.ru full
Antígeno Australia Arteria umbilical Símbolo químico del oro
Antígeno Australia Arteria umbilical Símbolo químico del oro... via esacademic.com
Antígeno Australia Arteria umbilical Símbolo químico del oro
Antígeno Australia Arteria umbilical Símbolo químico del oro... via esacademic.com
einen kalauer von russisch auf deutsch
https://ift.tt/2ZdLxq6
via Academic summary
https://ift.tt/2ZdLxq6
Sich die Webseite zu merken. Alle Sprachen Abchasisch Adyghe Afrikaans Ainu Akan Albanisch Alsacien Altaische Sprachen Altostslawische Sprache Arabisch Aragonese Armenisch Aromunische...via Academic summary
Academic dictionaries and encyclopedias
Übersetzungen — einen kalauer — von russisch — auf deutsch
Übersetzungen — einen kalauer — von russisch — auf deutsch — 1
для мессенжера von russisch auf deutsch
https://ift.tt/2ObUrht
via Academic summary
https://ift.tt/2ObUrht
Übersetzungen — для+мессенжера — von russisch — auf deutsch — 39...via Academic summary
Academic dictionaries and encyclopedias
Übersetzungen — для мессенжера — von russisch — auf deutsch
Übersetzungen — для мессенжера — von russisch — auf deutsch — 39
https://ift.tt/3d3cq51 › Производители
https://ift.tt/2U64SGY
via Academic summary
https://ift.tt/2U64SGY
Чем же бутылки Nalgene отличаются от всех остальных? Давайте разберемся. BPA- FREE При изготовлении подавляющего большинства бутылок ...via Academic summary
forma-odezhda.ru
Форма одежды - магазин форменной одежды полиции, МЧС, МВД
Военторг Форма одежды - уставная форма, камуфляж, военная одежда, военторги москвы, армейский магазин, военный магазин, форма полиции, форма МЧС
Danaiden - Das Wörterbuch der Idiome - DeAcademic
https://ift.tt/2UYlpfF
via Academic summary
https://ift.tt/2UYlpfF
Eine Danaidenarbeit verrichten: eine unendlich mühevolle und trotzdem vergebliche Arbeit tun müssen. Ebenso bedeuten die Redensart: Ins Danaidenfaß ...via Academic summary
Academic dictionaries and encyclopedias
Danaiden
Eine Danaidenarbeit verrichten: eine unendlich mühevolle und trotzdem vergebliche Arbeit tun müssen. Ebenso bedeuten die Redensart: Ins Danaidenfaß schöpfen und Das Faß der Danaiden füllen wollen, daß vergebliche Anstrengungen unternommen…
https://enciclopedia_universal.esacademic.com › nivómetro
https://enciclopedia_universal.esacademic.com/223527/niv%C3%B3metro
via Academic summary
https://enciclopedia_universal.esacademic.com/223527/niv%C3%B3metro
Mira otros diccionarios: Nivómetro — El nivómetro es un aparato diseñado para medir la profundidad y espesor de la capa de nieve, aguanieve o granizo y ...via Academic summary
control de ganancia automática instantáneo von englisch
https://ift.tt/2Zhmkv1
via Academic summary
https://ift.tt/2Zhmkv1
Sich die Webseite zu merken. Alle Sprachen Abchasisch Adyghe Afrikaans Ainu Akan Albanisch Alsacien Altaische Sprachen Altostslawische Sprache Arabisch Aragonese Armenisch Aromunische...via Academic summary
Academic dictionaries and encyclopedias
Übersetzungen — control de ganancia automática instantáneo — von englisch —
Übersetzungen — control de ganancia automática instantáneo — von englisch — — 1
academic2.ru full
Inventiva Announces Trading Resumption Of Its Ordinary Shares On Euronext Paris
Saving page now...
https://www.thestreet.com/press-releases/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-15369876
As it appears live July 10, 2020 4:16:06 PM UTC https://web.archive.org/static/images/logo_WM.png
https://web.archive.org/save/_embed/https://www.thestreet.com/.image/MTY4NjI4Nzg1MDUzMjQ3MTEx/thestreet.svg Join UsReceive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's Terms and Policy
Already have an account? Login here
Daix (France), July 10, 2020 - INVENTIVA S.A. (Euronext Paris: IVA) (" Inventiva" or the " Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (" NASH"), mucopolysaccharidoses (" MPS") and other diseases with significant unmet medical need, announced the trading resumption of its ordinary shares on Euronext in Paris (" Euronext Paris") as from 3:30 pm CET.
Trading in the ordinary shares of Inventiva was halted at the request of the Company on July 10, 2020 from 9:00 am CET in connection with its previously announced global offering, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company's American Depositary Shares on the Nasdaq Global Market.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company [...]
Inventiva Announces Trading Resumption Of Its Ordinary Shares On Euronext Paris
Saving page now...
https://www.thestreet.com/press-releases/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-15369876
As it appears live July 10, 2020 4:16:06 PM UTC https://web.archive.org/static/images/logo_WM.png
https://web.archive.org/save/_embed/https://www.thestreet.com/.image/MTY4NjI4Nzg1MDUzMjQ3MTEx/thestreet.svg Join UsReceive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's Terms and Policy
Already have an account? Login here
Daix (France), July 10, 2020 - INVENTIVA S.A. (Euronext Paris: IVA) (" Inventiva" or the " Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (" NASH"), mucopolysaccharidoses (" MPS") and other diseases with significant unmet medical need, announced the trading resumption of its ordinary shares on Euronext in Paris (" Euronext Paris") as from 3:30 pm CET.
Trading in the ordinary shares of Inventiva was halted at the request of the Company on July 10, 2020 from 9:00 am CET in connection with its previously announced global offering, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company's American Depositary Shares on the Nasdaq Global Market.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company [...]
TheStreet
Inventiva Announces Trading Resumption Of Its Ordinary Shares On Euronext Paris
Daix (France), July 10, 2020 - INVENTIVA S.A. (Euronext Paris: IVA) (" Inventiva" or the " Company"), a clinical-stage biopharmaceutical company focused
Товары из категории сабо Купить - Интернет …
https://ift.tt/30X6eaV
via Academic summary
https://ift.tt/30X6eaV
ГОСТ ГОСТ 1135-2005 Тип продукции сабо Материал натуральная кожа Материал верха натуральная кожа Артикул М602-00 Метод крепления подошвы литьевой Материал подошвы поливинилхлорид (ПВХ) Стелька спилок Объём 0,0033 м3 Вес 0,65 кг ...via Academic summary
forma-odezhda.ru
Товары из категории сабо Купить - Интернет-магазин форменной одежды forma-odezhda.ru
Товары с тегом сабо
academic2.ru 🎓²
academic2.ru full Inventiva Announces Trading Resumption Of Its Ordinary Shares On Euronext Paris Saving page now... https://www.thestreet.com/press-releases/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-15369876 As it appears…
listed on compartment C of the regulated market of Euronext Paris. (Euronext: IVA - ISIN: FR0013233012).
Important Notice
This press release contains certain forward-looking statements with respect to the proposed trading resumption. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.
Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
Forward-Looking Statements
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The distribution of this document may, in certain jurisdiction, be restricted by local legislations. Persons who comes into possession of this document are required to inform themselves about and to observe any such potential local restrictions.
A French listing prospectus comprising (i) the 2019 Universal Registration Document filed with the AMF on June 19, 2020 (document d'enregistrement universel 2019) under number D. 20-0551, as completed by an amendment to such Universal Registration Document, filed with the AMF on July 10, 2020 under number D 20-0551-A01, and (ii) a Securities Note (Note d'opération), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org. Following the filing of the amendment to the universal registration document with the AMF, copies of Company's 2019 Universal Registration Document, as amended, will be available free of charge at the Company's head office located at 50 rue de Dijon, 21121 Daix, France.
European Economic Area
In relation to each Member State of the European Economic Area (each, a ''Member State'') no offer to the public of ordinary shares and ADSs may be made in that Member State other than:
* to any legal entity which is a ''qualified investor'' as defined in the Prospectus Regulation;
* to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the Underwriters for any such offer; or
* in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a ''qualified investor'' as defined in the Prospectus Regulation.
For the purposes of this provision, the expression an ''offer to the public'' in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary share[...]
Important Notice
This press release contains certain forward-looking statements with respect to the proposed trading resumption. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.
Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
Forward-Looking Statements
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The distribution of this document may, in certain jurisdiction, be restricted by local legislations. Persons who comes into possession of this document are required to inform themselves about and to observe any such potential local restrictions.
A French listing prospectus comprising (i) the 2019 Universal Registration Document filed with the AMF on June 19, 2020 (document d'enregistrement universel 2019) under number D. 20-0551, as completed by an amendment to such Universal Registration Document, filed with the AMF on July 10, 2020 under number D 20-0551-A01, and (ii) a Securities Note (Note d'opération), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org. Following the filing of the amendment to the universal registration document with the AMF, copies of Company's 2019 Universal Registration Document, as amended, will be available free of charge at the Company's head office located at 50 rue de Dijon, 21121 Daix, France.
European Economic Area
In relation to each Member State of the European Economic Area (each, a ''Member State'') no offer to the public of ordinary shares and ADSs may be made in that Member State other than:
* to any legal entity which is a ''qualified investor'' as defined in the Prospectus Regulation;
* to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the Underwriters for any such offer; or
* in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a ''qualified investor'' as defined in the Prospectus Regulation.
For the purposes of this provision, the expression an ''offer to the public'' in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary share[...]